Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
Kalyan Roy: Hematopoietic Stem Cell Transplantation in Thalassaemia 
Kalyan Roy/ LinkedIn
May 29, 2026, 13:39

Kalyan Roy: Hematopoietic Stem Cell Transplantation in Thalassaemia 

Kalyan Roy, Transfusion Medicine Specialist at Square Hospitals LTD, shared a post on LinkedIn:

“Hematopoietic Stem Cell Transplantation (HSCT) in Thalassaemia

A Potentially Curative Therapy for Transfusion-Dependent Patients

For decades, treatment of severe thalassaemia mainly depended on:

  • Lifelong blood transfusions
  • Iron chelation therapy
  • Continuous medical monitoring

Today, Hematopoietic Stem Cell Transplantation (HSCT) remains the most established curative treatment for severe thalassaemia.

What is HSCT?

HSCT is a procedure in which:Diseased or defective bone marrow is replaced with healthy hematopoietic stem cells.

The goal is to restore:

  • Normal red blood cell production
  • Functional hemoglobin synthesis
  • Transfusion independence

Who May Benefit?

  • β-thalassaemia major
  • Transfusion-dependent thalassaemia patients

Best outcomes are generally seen in:

  • Younger patients
  • Patients with minimal organ damage
  • HLA-matched sibling donors
  • Early transplantation before severe iron overload complications

Sources of Stem Cells

Stem cells may be obtained from:

  • Bone marrow
  • Peripheral blood stem cells
  • Umbilical cord blood

How Does HSCT Work?

  • Step 1 — Pre-Transplant Evaluation
  • Step 2 — Conditioning Therapy
    Chemotherapy is administered to suppress diseased marrow and prepare the body for transplantation.
  • Step 3 — Stem Cell Infusion
    Healthy donor stem cells are infused intravenously.
    These cells migrate to the bone marrow and begin producing healthy blood cells.
  • Step 4 — Engraftment and Recovery

Over time:

Donor stem cells establish normal hematopoiesis.

Possible Complications

Although HSCT offers curative potential, it remains a complex procedure.

Possible complications include:

  • Graft-versus-host disease (GVHD)
  • Severe infections
  • Graft failure
  • Organ toxicity
  • Infertility risk
  • Transplant-related mortality

Factors Affecting Outcome

Transplant success depends on:

  • Age at transplantation
  • Degree of iron overload
  • Liver status
  • Donor compatibility
  • Infection control
  • Overall clinical condition

Early transplantation generally provides better outcomes.

HSCT vs Lifelong Transfusion 

  • Conventional therapy
  • Regular transfusions
  • Iron chelation
  • Long-term supportive care

But:

Lifelong dependence continues.

  • HSCT
  • Potential cure
  • Possible transfusion independence
  • Reduced long-term iron overload

However:

Significant procedural risks exist.

Final Reflection

For selected thalassaemia patients, it offers the possibility of:

  • Cure
  • Freedom from lifelong transfusions
  • Improved long-term quality of life.”

Kalyan Roy: Hematopoietic Stem Cell Transplantation in Thalassaemia 

Other posts featuring Kalyan Roy on Hemostasis Today.

Health Hematology Hemostasis Hemostasis News Hemostasis Today Kalyan Roy
NewsFeed